Drug Profile
HMBD 002
Alternative Names: anti-VISTA antibody - Hummingbird Bioscience; HMBD-002; HMBD-002-V4; HMBD-002-V4C26Latest Information Update: 04 Feb 2022
Price :
$50
*
At a glance
- Originator Hummingbird Bioscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; VISTA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 01 Jan 2022 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05082610)
- 01 Jan 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05082610)
- 25 Oct 2021 Hummingbird Bioscience and Merck enter into a clinical trial collaboration agreement to develop HMBD 002 in combination with pembrolizumab.